Zanubrutinib (Mechanism of Action)

In this article, we will discuss Zanubrutinib (Mechanism of Action). So, let’s get started.

Mechanism of Action

Zanubrutinib is a small-molecule inhibitor of BTK. Zanubrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, zanubrutinib inhibited malignant B-cell proliferation and reduced tumor growth.

Pharmacodynamics

BTK Occupancy in PBMCs and Lymph Nodes
The median steady-state BTK occupancy in peripheral blood mononuclear cells was maintained at 100% over 24 hours at a total daily dose of 320 mg in patients with B-cell malignancies. The median steady-state BTK occupancy in lymph nodes was 94% to 100% following the approved recommended dosage.

Cardiac Electrophysiology

At the approved recommended doses (160 mg twice daily or 320 mg once daily), there were no clinically relevant effects on the QTc interval. The effect of Zanubrutinib on the QTc interval above the therapeutic exposure has not been evaluated.

One thought on “Zanubrutinib (Mechanism of Action)

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.